Daunorubicin-prednisone remission induction with hydroxyurea maintenance in acute non-lymphocytic leukemia
โ Scribed by Clara D. Bloomfield; Richard D. Brunning; Athanasios Theologides; B. J. Kennedy
- Publisher
- John Wiley and Sons
- Year
- 1973
- Tongue
- English
- Weight
- 635 KB
- Volume
- 31
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Therapy for acute lymphocytic leukemia (ALL) has been less successful in adults than in children. Many centers treat all adult leukemia with the same regimen. We have used vincristine and prednisone for initial therapy in 14 adults with ALL since 1971 and have followed a treatment regimen developed
Twenty-eight patients with acute non-lymphoblastic leukemia (ANLL) were started on induction chemotherapy consisting of Cytosine Arbinoside (Ara C) and 6 thioguanine (TG). Daunoruhicin (DNR) was used selectively in 20 of 28 patients who failed to respond by day 14 to the Ara C and TG combination. Se
## Background: The authors report the occurrence of fatal or near-fatal sepsis in 16 of 38 children with newly diagnosed acute lymphoblastic leukemia (all) treated with a new induction regimen that differed from its predecessor by the substitution of dexamethasone for prednisone. ## Methods: The
Second remission induction rates for vincristine and prednisone alone (VP) and vincristine, L-asparaginase, and prednisone (VLP) are compared for children with acute lymphocytic leukemia. No evidence of a significant difference between the second induction complete remission rate for VP (78.6%) and